390 related articles for article (PubMed ID: 32757473)
21. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
Tang G; Medeiros LJ; Wang SA
Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
[TBL] [Abstract][Full Text] [Related]
22. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
23. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
24. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
Guo J; Chang CK; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
[TBL] [Abstract][Full Text] [Related]
25. [Recent advances in the treatment of myelodysplastic syndromes].
Gelsi-Boyer V; Vey N
Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
Bejar R
Curr Hematol Malig Rep; 2015 Sep; 10(3):282-91. PubMed ID: 26126599
[TBL] [Abstract][Full Text] [Related]
27. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
[TBL] [Abstract][Full Text] [Related]
28. Flow Cytometric Findings in Clonal Cytopenia of Undetermined Significance.
Nirmalanantham P; Sakhi R; Beck R; Oduro K; Gadde R; Ryder C; Yoest J; Sadri N; Meyerson HJ
Am J Clin Pathol; 2022 Feb; 157(2):219-230. PubMed ID: 34542558
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM; Faltas B; Douglas Smith B; Gore S
J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Markers of Myelodysplastic Syndromes.
Veryaskina YA; Titov SE; Kovynev IB; Pospelova TI; Zhimulev IF
Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727068
[TBL] [Abstract][Full Text] [Related]
31. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.
Kwok B; Hall JM; Witte JS; Xu Y; Reddy P; Lin K; Flamholz R; Dabbas B; Yung A; Al-Hafidh J; Balmert E; Vaupel C; El Hader C; McGinniss MJ; Nahas SA; Kines J; Bejar R
Blood; 2015 Nov; 126(21):2355-61. PubMed ID: 26429975
[TBL] [Abstract][Full Text] [Related]
32. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
33. The current approach to the diagnosis of myelodysplastic syndromes
Weinberg OK; Hasserjian RP
Semin Hematol; 2019 Jan; 56(1):15-21. PubMed ID: 30573039
[TBL] [Abstract][Full Text] [Related]
34. Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia.
Jajosky AN; Sadri N; Meyerson HJ; Oduro KA; Kelkar A; Fitzgerald B; Tomlinson B; Moore EM; Beck RC
Eur J Haematol; 2021 Apr; 106(4):500-507. PubMed ID: 33386622
[TBL] [Abstract][Full Text] [Related]
35. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
[TBL] [Abstract][Full Text] [Related]
36. Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.
Moyo TK; Savona MR
Curr Hematol Malig Rep; 2016 Dec; 11(6):441-448. PubMed ID: 27734261
[TBL] [Abstract][Full Text] [Related]
37. Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management.
Valent P
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101137. PubMed ID: 32460976
[TBL] [Abstract][Full Text] [Related]
38. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
39. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic syndromes.
Adès L; Itzykson R; Fenaux P
Lancet; 2014 Jun; 383(9936):2239-52. PubMed ID: 24656536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]